

Vaccine Technology IV 2012

**Albufeira, Portugal
20 – 25 May 2012**

Editors:

**B. Buckland
J. Aunins**

**P. Alves
K. Jansen**

ISBN: 978-1-63439-947-0

Printed from e-media with permission by:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571



Some format issues inherent in the e-media version may also appear in this print version.

Copyright© (2012) by Engineering Conferences International
All rights reserved.

Printed by Curran Associates, Inc. (2015)

For permission requests, please contact Engineering Conferences International
at the address below.

Engineering Conferences International
32 Broadway, Suite 314
New York, NY 10004

Phone: (212) 514-6760

Fax: (212) 514-6030

info@engconfintl.org

Additional copies of this publication are available from:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571 USA
Phone: 845-758-0400
Fax: 845-758-2634
Email: curran@proceedings.com
Web: www.proceedings.com

TABLE OF CONTENTS

SESSION I: VACCINE TARGET IDENTIFICATION AND VALIDATION

| | |
|--|----|
| COMPREHENSIVE T-CELL ANTIGEN DISCOVERY USING A GENOMIC APPROACH | 1 |
| <i>Jessica Baker</i> | |
| RATIONAL DESIGN OF A FULLY SYNTHETIC NANOPARTICLE-BASED VACCINE FOR SMOKING CESSATIO | 16 |
| <i>Takashi Kishimoto</i> | |
| TOLEROGENIC VACCINATION EXPLOITING APOPTOTIC MECHANISMS VIA ERYTHROCYTE-TO- HEPATIC/SPLENIC TARGETING | 29 |
| <i>Jeffrey Hubbell</i> | |
| DEVELOPMENT OF A VACCINE AGAINST CLOSTRIDIUM DIFFICILE INFECTION (CDI): DESIGN, PURIFICATION, AND BIOLOGICAL ACTIVITIES OF THE RECOMBINANT TOXIN 1 ANTIGENS | 46 |
| <i>Jerzy Karczewski</i> | |

SESSION II: TECHNOLOGY CHALLENGES IN DEVELOPING WORLD MARKET (PART 1)

| | |
|--|-----|
| 111 YEARS PRODUCING IMMUNOBIOLOGICALS: NEW CHALLENGES | 62 |
| <i>Jorge Kalil</i> | |
| BRINGING VACCINE MANUFACTURING CAPABILITIES TO THE DEVELOPING WORLD | 77 |
| <i>George Robertson</i> | |
| RECOMBINANT VLP BASED HUMAN VACCINES FOR EMERGING MARKETS | 91 |
| <i>Qinjian Zhao</i> | |
| ESTABLISHING HUMAN VACCINE MANUFACTURING IN SOUTHERN AFRICA | 113 |
| <i>Morena Makhoana</i> | |

SESSION III: LATE STAGE And RECENTLY LAUNCHED VACCINES

| | |
|---|-----|
| RECOMBINANT INFLUENZA VACCINE | 126 |
| <i>Manon Cox</i> | |
| PROCESS UNDERSTANDING APPROACH FOR A LATE-STAGE RECOMBINANT PROTEIN VACCINE PRODUCED IN SACCHAROMYCES CEREVISIAE | 142 |
| <i>Jose Manuel Otero, Brian Mickus, Amanda Schallop, Brian Doyle, Nedim Altaras</i> | |

SESSION II: TECHNOLOGY CHALLENGES IN DEVELOPING WORLD MARKET (PART 2)

| | |
|--|-----|
| CHALLENGES IN DEVELOPMENT OF AN ANTI-IDIOTYPIC CANCER VACCINE | 161 |
| <i>Adolfo Castillo</i> | |
| EXPECTATION OF CHINA'S CONTRIBUTION TO WORLD VACCINE DEVELOPMENT AND SUPPLIES: STATUS, STRATEGY AND INTERNATIONAL APPROACH | 174 |
| <i>Li Shi</i> | |
| RABIES VIRUS-LIKE PARTICLES EXPRESSED IN HEK293 CELLS | 204 |
| <i>Diego Fontana, Ricardo Kratje, Marina Etcheverrigaray</i> | |
| THE ROLE OF PUBLIC-PRIVATE PARTNERSHIPS IN ADVANCING VACCINE TECHNOLOGIES AND IMPROVING VACCINE EFFECTIVENESS AND DELIVERY FOR DEVELOPING COUNTRIES | 216 |
| <i>Ray Cummings</i> | |
| CHALLENGES IN BATCH PRODUCTION OF MALARIA VACCINES | 226 |
| <i>Nicolas Havelange</i> | |

SESSION IV: VACCINE STABILITY, CHARACTERIZATION AND DELIVERY

| | |
|---|-----|
| FORMULATION AND STABILITY OF A CHIKUNGUNYA VIRUS-LIKE PARTICLE (CHIKV VLP) BASED VACCINE | 239 |
| <i>Rhicard Schwartz</i> | |
| HIGH THROUGHPUT FORMULATION DESIGN FOR A STABLE LYOPHILIZED VIRUS-LIKE PARTICLE VACCINE AGAINST GROUP A STREPTOCOCCU | 251 |
| <i>Yap Chuan</i> | |
| CHALLENGES IN OPTIMIZING FORMULATIONS FOR MULTI- ANTIGEN VACCINES | 273 |
| <i>Lakshmi Khandke</i> | |
| A PROTEIN-FREE PROCESS AND PRODUCT PROTECTION SYSTEM | 284 |
| <i>Stephen Ward</i> | |

SESSION V: VETERINARY VACCINES

| | |
|--|-----|
| A NEW SUCCESSFUL VACCINE AGAINST BABESIOSIS: ANY USE FOR MALARIA? | 301 |
| <i>Thep Schetters</i> | |
| LEISHMANIASIS VACCINE DEVELOPMENT: ANIMALS AS MODELS AND PATIENTS | 317 |
| <i>Steven Reid</i> | |
| RIFT VALLEY FEVER: NEXT GENERATION VACCINES FOR AN OLD FOE | 338 |
| <i>Brian Bird</i> | |
| FUNCTIONAL GENOMICS AS A TOOL TO DEFINE A MOLECULAR SIGNATURE OF EFFECTIVE VACCINATION AGAINST FOOT AND MOUTH DISEASE VIRUS | 353 |
| <i>Jose Chabalgoity</i> | |

SESSION VI: ONCOLOGY AND THERAPEUTIC VACCINES

| | |
|--|-----|
| ONCOLYTIC VIRUSES AS CANCER THERAPIES | 377 |
| <i>Stephen Rusell</i> | |
| THE CMC CHALLENGES IN DEVELOPING AN ONCOLYTIC IMMUNOTHERAPY | 414 |
| <i>Colin Love</i> | |
| PROCESS DEVELOPMENT FOR A PEPTIDE CONJUGATED QBETAVIRUS LIKE PARTICLE (VLP) VACCINE | 433 |
| <i>Jennifer Thorn</i> | |
| CHIMPANZEE AD VECTOR TECHNOLOGY PLATFORM FOR PROPHYLACTIC AND THERAPEUTIC GENETIC VACCINE APPLICATIONS | 445 |
| <i>Stefano Colloca</i> | |
| CERVICAL CANCER IMMUNOTHERAPY: INDUCTION OF HPV SPECIFIC CTLS IN HUMAN VOLUNTEERS AFTER VGX-3100 IMMUNIZATION | 475 |
| <i>Niranjan Sardesai</i> | |

SESSION VII: BIOPROCESS DEVELOPMENT AND ANALYTICAL TOOLS

| | |
|---|-----|
| MICROBIAL FERMENTATION: NEW TOOLS TO SPEED-UP VACCINE ANTIGEN DEVELOPMENT AND INCREASE PROCESS KNOWLEDGE | 492 |
| <i>Catherine Jourdat</i> | |
| BACTERIAL EXPRESSION OF A VLP SUB-UNIT FOR RAPID AND CHEAP INFLUENZA VACCINATION | 504 |
| <i>Anton Middelberg</i> | |
| HIGH CELL DENSITY CULTIVATIONS FOR INFLUENZA VIRUS PRODUCTION USING SUSPENSION CELLS | 523 |
| <i>Y. Genzel, T. Vogel, J. Buck, I. Behrendt, G. Schiedner, I. Jordan, U. Reichl</i> | |
| RMCE-BASED SF9 CELL FACTORY FOR PRODUCTION OF MULTI-MERIC VLPS | 539 |
| <i>Ana Teixeira</i> | |
| SYSTEMATICALLY CHARACTERIZING ADVENTITIOUS AGENT TESTS FOR BIOLOGICS | 552 |
| <i>Rebecca Sheets</i> | |
| AUTOMATION AND MULTIPLEXING OF IMMUNOASSAYS: IMPROVING PRECISION AND THROUGHPUT | 570 |
| <i>Iliia Tikhonov</i> | |

| | |
|--|------------|
| DEVELOPING A SUITE OF ANALYTICS TO SUPPORT PROCESS DEVELOPMENT FOR THE MANUFACTURE OF POLYSACCHARIDES | 591 |
| <i>Aaron Noyes, Ranga Godavarti, Nigel Titchener-Hooker, Jonathan Coffman, Tarit Mukhopadhyay</i> | |

SESSION VIII: BIODEFENSE, PANDEMIC & EMERGING DISEASE VACCINES: (PART 1)

| | |
|---|------------|
| BUILDING PANDEMIC PREPAREDNESS THROUGH A SUSTAINABLE ENTERPRISE FOR INFLUENZA VACCINES | 603 |
| <i>Robert Huebner</i> | |

SESSION IX: NEW TECHNOLOGIES AND APPROACHES

| | |
|--|------------|
| BACTERIUM-LIKE PARTICLES AS DELIVERY VEHICLES FOR MULTIMERIC ANTIGENS | 616 |
| <i>Kees Leenhouts</i> | |
| MUTIPLY ACTIVATED VLP INFLUENZA VACCINES | 641 |
| <i>James Swartz, Yuan Lu, John Welsh, Wei Chan</i> | |
| ENDOTOXIN-FREE E. COLI HOSTS FOR VACCINE DISCOVERY AND PRODUCTION | 664 |
| <i>David Bramhill</i> | |
| NOVEL GLYCOCONJUGATE VACCINES BASED ON RATIONALLY DESIGNED SYNTHETIC CARBOHYDRATE ANTIGENS | 686 |
| <i>Stewart Campbell</i> | |
| UTILIZING ‘OMICS TOOLS TO INVESTIGATE THE IMPACT OF PROCESS CHANGES ON PRODUCT QUALITY IN CELL CULTURE-BASED INFLUENZA VACCINE PRODUCTION | 705 |
| <i>E. Rapp, J. Rodig, J. Schwarzer, D. Hoepfer, R. Hennig, Y. Genzel, U. Reichl</i> | |
| MONOLITHIC COLUMNS FOR PURIFICATION AND IN-PROCESS CONTROL OF VIRUSES AND VIRUS-LIKE PARTICLES | 734 |
| <i>Lidija Urbas, Milos Barut</i> | |

SESSION VIII: BIODEFENSE, PANDEMIC & EMERGING DISEASE VACCINES: (PART 2)

| | |
|---|------------|
| PLANT-MADE INFLUENZA VIRUS-LIKE PARTICLES: FOR PANDEMIC AND BEYOND | 759 |
| <i>Nathalie Charland</i> | |
| FLUNISYN: ADVANCED DEVELOPMENT OF A SYNTHETIC UNIVERSAL INFLUENZA T-CELL VACCINE..... | 772 |
| <i>Campbell Bunce</i> | |
| PURIFICATION OF CELL-BASED INFLUENZA H5N1 VIRUSES BY LIQUID CHROMATOGRAPHY TECHNOLOGIES | 779 |
| <i>Alan Yung-Chih Hu</i> | |
| VIRAL SENSITIZER TECHNOLOGY IMPROVES YIELD OF MODIFIED VACCINIA ANKARA FROM AVAILABLE CELL SUBSTRATES | 794 |
| <i>Facrice Le Boeuf</i> | |
| SUSPENSION VERO CELLS (SVERO) FOR POLIOVIRUS PRODUCTION: EFFECT OF CULTURE PASSAGE ON GROWTH KINETICS AND PRODUCTIVITY | 804 |
| <i>Guillermina Forno</i> | |
| Author Index | |